Feature

ASCO to award $50,000 young investigator grant to study MCL


 

Early-career researchers who are interested in studying mantle cell lymphoma can now apply for a $50,000 grant from the American Society of Clinical Oncology’s Conquer Cancer foundation.

The young investigator grant is for a 1-year period and the award is used to fund a project focused on clinical or translational research on the clinical biology, natural history, prevention, screening, diagnosis, therapy, or epidemiology of MCL.

The purpose of this annual award, according to ASCO, is to fund physicians during the transition from a fellowship program to a faculty appointment.

Eligible applicants must be physicians currently in the last 2 years of final subspecialty training and within 10 years of having obtained his or her medical degree. Additionally, applicants must be planning a research career in clinical oncology, with a focus on MCL.

The grant selection committee’s primary criteria include the significance and originality of the proposed study and hypothesis, the feasibility of the experiment and methodology, whether it has an appropriate and detailed statistical analysis plan, and if the research is patient oriented.

The application deadline is Jan. 7, 2020, and the award term is July 1, 2020–June 30, 2021.

Application instructions are available on the ASCO website.

Recommended Reading

CD23 expression linked to improved survival in MCL
MDedge Hematology and Oncology
Obinutuzumab provides strong early responses in untreated MCL
MDedge Hematology and Oncology
Bispecific CAR T-cell therapy yields complete responses in relapsed/refractory non-Hodgkin lymphomas
MDedge Hematology and Oncology
Flavopiridol elicits poor response in mantle cell lymphoma, DLBCL
MDedge Hematology and Oncology
Low-dose radiation therapy looks effective in hard-to-treat MCL
MDedge Hematology and Oncology
Ibrutinib/rituximab effective, safe as frontline treatment for older patients with MCL
MDedge Hematology and Oncology
Ibrutinib-rituximab induction yields ‘unprecedented’ responses in MCL
MDedge Hematology and Oncology
Rituximab, bendamustine look better than chemo alone in MCL
MDedge Hematology and Oncology
Staging PET/CT better defines extent of mantle cell lymphoma
MDedge Hematology and Oncology
Follow-up shows favorable results with acalabrutinib in MCL
MDedge Hematology and Oncology